Effects of canagliflozin on myocardial microvascular density, oxidative stress, and proteomic profile
Authors:
Open Access
- 22 September 2023
- journal article
- research article
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 6
Abstract
No abstract availableKeywords
Funding Information
- NIH
- National Heart, Lung, and Blood Institute (1F32HL160063-01, R01HL128831, 1R01HL133624, R01HL46716, T32 GM065085, T32HL160517)
This publication has 22 references indexed in Scilit:
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic HeartJACC: Basic To Translational Science, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic ControlCirculation, 2018
- QuPath: Open source software for digital pathology image analysisScientific Reports, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Pathophysiology of LV Remodeling in Survivors of STEMIJACC: Cardiovascular Imaging, 2015
- The ubiquitin proteasome system and myocardial ischemiaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndromeThe Journal of Thoracic and Cardiovascular Surgery, 2012
- AMP-Activated Protein Kinase Regulation and Biological Actions in the HeartCirculation Research, 2012